GlaxoSmithKline has opted to cease pursuit of approval for its antiemetic Rezonic/Zunrisa (casopitant), and is pulling all ongoing marketing applications. "After regulatory consultation," the firm explained, its assessment was that "significant further safety data would be required to support the registration of casopitant on a worldwide basis, which would take considerable time to produce." GSK had been pursuing a set of indications that would have been an attractive commercial package: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic chemotherapy, and prevention of postoperative nausea and vomiting. The drug had been slated for FDA advisory committee review in May, but the meeting was cancelled. In June, FDA issued a "complete response" letter for the application. The European Medicines Agency will make further details available following the Oct. 19-22 meeting of the Committee for Medicinal Products for Human Use. The NK-1 antagonist was a novel mechanism for the antiemetic field, and would have retained an oncology supportive care foothold to account for the loss of GSK's Zofran (ondansetron) to generic competition
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.
Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.
